GlaxoSmithKline Plc reported a sales decline of 2% in the third quarter of 2010 to £6.8 billion. However, excluding events such as the suspension of Avandia (rosiglitazone) in Europe and restrictions in the US, sales rose by an underlying 6%. ---Subscribe to MedNous to access this article--- Company News
